Home/Prelude Therapeutics/Not explicitly listed in provided content
NE

Not explicitly listed in provided content

CEO

Prelude Therapeutics

Therapeutic Areas

Prelude Therapeutics Pipeline

DrugIndicationPhase
PRT3789SMARCA4-mutant cancersPhase 1/2
PRT2527Hematologic malignancies and solid tumorsPhase 1/2
PRT3645Cancers dependent on CDK4/6Phase 1
PRT543/PRT811MTAP-deleted cancersPhase 1
PRT13722ER+ breast cancer and other solid tumorsPreclinical
PRT12396Myeloproliferative neoplasms (JAK2V617F)IND Cleared
Precision DACsUndisclosed solid tumorsDiscovery